Latest News
Aldeyra Therapeutics, Inc.
- Aldeyra Therapeutics, Inc. Estimates – GETTEX:137
- We Think Aldeyra Therapeutics (NASDAQ:ALDX) Can Afford To Drive Business Growth
- Which of Aldeyra Therapeutics (NASDAQ:ALDX), SmartKem (NASDAQ:SMTK), Nexentis Technologies (NASDAQ:NXTS), Powell Max (NASDAQ:PMAX) or Beam Global (NASDAQ:BEEM) Trades Between 50 and 90 Cents in Pre-Market?
- Why Is Aldeyra Therapeutics (NASDAQ:ALDX) Up 7.83% Pre-Market? The Catalyst, the Fundamentals and the Risks Before the Open
- Which of Upstream Bio (NASDAQ:UPB), Biofrontera (NASDAQ:BFRI), Aldeyra Therapeutics (NASDAQ:ALDX), KALA BIO (NASDAQ:KALA) or Inovio Pharmaceuticals (NASDAQ:INO) Is the Best Biotech or Pharma Gainer in Pre-Market?
- Aldeyra Plans FDRR to Appeal FDA Reproxalap CRL for Dry Eye
- H.C. Wainwright reiterates Neutral on Aldeyra stock at $2 target
- Aldeyra to appeal FDA rejection of dry eye drug reproxalap By Investing.com
- Aldeyra to appeal FDA rejection of reproxalap as a treatment for dry eye disease
- Form 8K Aldeyra Therapeutics Inc For: 29 September By Investing.com
- Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally
- Aldeyra Plans to Appeal FDA Rejection of Reproxalap NDA
Headlines from the last 30 days, linking to the original publishers. See all market news →